CYP19A1 and breast carcinoma: Among the various breast cancer subtypes, the most common tumors are estrogen receptor-positive (ER+) [1,3], which make them suitable for endocrine therapy, namely with the aromatase inhibitors (AIs), and the anti-estrogens tamoxifen and fulvestrant.